Biogen reveals Tysabri failure in stroke trial
Biogen has confirmed that it will not pursue further development of Tysabri in acute ischemic stroke (AIS) after a mid-stage study missed primary and secondary efficacy goals.
Read More
Tag: AIS
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
